Molbio Diagnostics Ltd

Molbio Diagnostics Earnings Call Transcript: Key Takeaways

H1 FY27 revenue of ₹667 Cr was slightly below ₹680 Cr a year ago. Management blamed a one-month government rate-contract delay and reiterated 25% FY27 growth guidance.

Call

Guides 25% growth

Molbio Diagnostics Other Announcement

Molbio Diagnostics filed CRISIL's monitoring agency report on IPO proceeds utilisation for the quarter ended 30 September 2026. The report states no deviation from the issue objects.

Molbio Diagnostics Investor Presentation: Key Takeaways

Q2 FY27 revenue ₹259 Cr (-55% YoY), PAT ₹7.7 Cr (-93%). H1 FY27 revenue ₹667 Cr (-2%), PAT ₹60 Cr (-27%). Management reiterates 25% FY27 topline growth target.

Call

Guides 25% growth

Molbio Diagnostics Q2 FY27 Results: Net Profit ₹7.7 Cr, Down 92.8% YoY

Molbio Diagnostics Ltd reported revenue from operations of ₹259 Cr (-55.4% YoY) and net profit of ₹7.7 Cr (-92.8% YoY) for Q2 FY27.

Key figure

Net profit ₹7.7 Cr · -92.8% YoY

Molbio Diagnostics Board Meeting Date

Molbio Diagnostics' Board is scheduled for November 5, 2026, to approve Q1 and H1 results. Trading window stays closed until 48 hours post-declaration.

Molbio Diagnostics Price Movement Clarification

Molbio Diagnostics responded to NSE's spurt-in-volume query, stating the movement is purely market-driven. No pending price-sensitive information is slated for disclosure.

Molbio Diagnostics Other Announcement

Molbio Diagnostics Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides information on promoter and public shareholding structures.

Molbio Diagnostics Capital Structure Change

Kotak Mahindra Mutual Fund acquired 5,70,000 Molbio Diagnostics shares in the open market on 08 October 2026. Its stake crossed 5% to 5.4834%.